The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals (SEHK:2616) for $44 million on December 21, 2023. This will be followed by a payment of up to 6 million USD upon completion of the transition. As a result, the licensing agreement with Servier will be terminated and CStone will be released from payment obligations of any remaining development and commercialization milestones.